Avaliação de parâmetros da resposta imunológica na co-infecção pelo HIV-1 e vírus das hepatites C e G (HGV/GBV-C)

Detalhes bibliográficos
Autor(a) principal: Baggio-Zappia, Giovana Lotici [UNIFESP]
Data de Publicação: 2009
Tipo de documento: Tese
Idioma: por
Título da fonte: Repositório Institucional da UNIFESP
Texto Completo: http://repositorio.unifesp.br/handle/11600/9067
Resumo: GBV-C co-infection is frequent in humans and could last for years without clinical symptoms. GBV-C is a flavivirus composed by a single positive RNA strain, closely related to HCV. Initially in its discovery GBV-C was associated with non-A-B hepatitis. However, subsequent studies failed to associate GBV-C with any known human disease and the virus became neglected until a series of studies associated the virus with prolonged survival in HIV infected recipients. Studies evaluating the co-infection presents conflicting results whereas triple HIV-HCV-GBV-C infection remains to be clarified. With the aim to evaluate the effect of GBV-C upon HIV and HIV-HCV co-infected patients, we included a cohort of 159 HIV-seropositive patients from CCDI-UNIFESP. The patients were tested for the presence of anti-E2 antibodies and GBV-C RNA. Of the 107 HIV seropositive patients negative to HCV infection, 41 (38,3%) were positive to GBV-C infection markers, of whom 17 (15,8%) were GBV-C viremic and 24 (22,4%) were positive to anti-E2 antibodies. Of the 52 HIV-HCV co-infected patients, 24 (46,1%) were positive to GBV-C infection markers, of whom 14 (26,9%) were viremic and 10 (19,2%) presented anti-E2 antibodies. Epidemiological data were collected; virological and immunological markers and also hepatic function were evaluated. Besides, IFN- and IL-2 production on CD4, T CD8 and T cells and CD38 activation marker on T CD4 and T CD8 cells were also evaluated. No significant differences on HIV viral load nor on T CD4 and T CD8 cell counts were observed, according to the infection profile. Immune response, evaluated by the IFN- and IL-2 production and by the CD38 expression did not differ among the groups studied. Univariate analysis demonstrated higher ALT, AST and GGT levels in the HIV-HCV co-infetced and HIVHCV- GBV-C triple infected patients. The multivariate analysis demonstrated that the GBV-C influences ALT levels on triple infected patients. Our results demonstrate that GBV-C does not exerts beneficial effects upon chronically HIV infected patients, unlike, it can cause hepatic overload, as demonstrated by the higher ALT levels in the HIV-HCV-GBV-C triple infected patients. In the light of these results, is reasonable to prudently consider this interaction until the possible pathological role of GBV-C on this situation is completely excluded.
id UFSP_dfec309865db6d1546c10c1b2bba0122
oai_identifier_str oai:repositorio.unifesp.br/:11600/9067
network_acronym_str UFSP
network_name_str Repositório Institucional da UNIFESP
repository_id_str 3465
spelling Avaliação de parâmetros da resposta imunológica na co-infecção pelo HIV-1 e vírus das hepatites C e G (HGV/GBV-C)Evaluation of parameters of immune response in co-infection with HIV-1 virus and hepatitis C and G (HGV / GBV-C)HIV-1Vírus GB CHepacivirusHIV-1GB virus CHepacivirusGBV-C co-infection is frequent in humans and could last for years without clinical symptoms. GBV-C is a flavivirus composed by a single positive RNA strain, closely related to HCV. Initially in its discovery GBV-C was associated with non-A-B hepatitis. However, subsequent studies failed to associate GBV-C with any known human disease and the virus became neglected until a series of studies associated the virus with prolonged survival in HIV infected recipients. Studies evaluating the co-infection presents conflicting results whereas triple HIV-HCV-GBV-C infection remains to be clarified. With the aim to evaluate the effect of GBV-C upon HIV and HIV-HCV co-infected patients, we included a cohort of 159 HIV-seropositive patients from CCDI-UNIFESP. The patients were tested for the presence of anti-E2 antibodies and GBV-C RNA. Of the 107 HIV seropositive patients negative to HCV infection, 41 (38,3%) were positive to GBV-C infection markers, of whom 17 (15,8%) were GBV-C viremic and 24 (22,4%) were positive to anti-E2 antibodies. Of the 52 HIV-HCV co-infected patients, 24 (46,1%) were positive to GBV-C infection markers, of whom 14 (26,9%) were viremic and 10 (19,2%) presented anti-E2 antibodies. Epidemiological data were collected; virological and immunological markers and also hepatic function were evaluated. Besides, IFN- and IL-2 production on CD4, T CD8 and T cells and CD38 activation marker on T CD4 and T CD8 cells were also evaluated. No significant differences on HIV viral load nor on T CD4 and T CD8 cell counts were observed, according to the infection profile. Immune response, evaluated by the IFN- and IL-2 production and by the CD38 expression did not differ among the groups studied. Univariate analysis demonstrated higher ALT, AST and GGT levels in the HIV-HCV co-infetced and HIVHCV- GBV-C triple infected patients. The multivariate analysis demonstrated that the GBV-C influences ALT levels on triple infected patients. Our results demonstrate that GBV-C does not exerts beneficial effects upon chronically HIV infected patients, unlike, it can cause hepatic overload, as demonstrated by the higher ALT levels in the HIV-HCV-GBV-C triple infected patients. In the light of these results, is reasonable to prudently consider this interaction until the possible pathological role of GBV-C on this situation is completely excluded.A infecção pelo GBV-C é freqüente em indivíduos saudáveis e pode permanecer por longos períodos sem a manifestação de sinais e sintomas clínicos. O GBV-C é um flavivírus composto por uma única fita de RNA de polaridade positiva, intimamente relacionado ao HCV. Inicialmente, o GBV-C foi associado à casos de hepatite fulminante de etiologia desconhecida. Estudos posteriores, no entanto, falharam em associar o GBV-C a qualquer doença humana conhecida e o vírus foi negligenciado por um longo período até que estudos sugeriram um efeito benéfico da co-infecção em pacientes HIV soropositivos. Os estudos envolvendo a co-infecção HIV-GBV-C apresentam resultados controversos enquanto trabalhos avaliando a tripla infecção HIV-HCV-GBV-C ainda são raros. Com o intuito de avaliar o efeito do GBV-C sobre pacientes HIV e HIV-HCV co-infectados crônicos, incluímos uma coorte de 159 pacientes HIV soropositivos triados a partir do CCDI-UNIFESP. Os pacientes foram testados para a presença de anticorpos anti-E2 e RNA do GBV-C. Dos 107 pacientes HIV, negativos para o HCV, 41 (38,3 por cento) apresentaram marcadores de infecção pelo GBV-C, dos quais 17 (15,8 por cento) eram virêmicos e 24 (22,4 por cento) positivos para anticorpos anti-E2. Dos 52 pacientes HIV-HCV co-infectados, 24 (46,1 por cento) apresentaram marcadores de infecção pelo GBV-C, dos quais 14 (26,9 por cento) apresentaram viremia e 10 (19,2 por cento) foram positivos para anticorpos anti-E2 do GBV-C. Foram coletados dados epidemiológicos e avaliados marcadores virológicos, imunológicos e de função hepática, além da produção de IFN-γ e IL-2 em células T CD4, T CD8 e Tγδ e da avaliação do marcador de ativação celular CD38 em células T CD4 e T CD8. Não foram observadas diferenças estatísticas nos níveis de CV do HIV e nem na contagem de linfócitos T CD4 e T CD8, de acordo com o perfil de infecção. A resposta imune, avaliada pela produção de citocinas IFN-γ e IL-2 e da expressão do marcador de ativação celular CD38 não diferiu entre os grupos avaliados. A análise univariada demonstrou aumento dos níveis de ALT, AST e GGT no grupo de pacientes HIV-HCV co-infectados e no grupo triplo infectado HIV-HCV- GBV-C. A análise multivariada revelou a influência do GBV-C sobre o aumento da ALT nos pacientes com tripla infecção. Os nossos dados demonstram que o GBV-C não exerce influência positiva sobre a infecção pelo HIV e pode causar sobrecarga hepática, como demonstrado pela elevação da ALT, em pacientes com tripla infecção. Dessa forma, esta interação deve ser vista com cautela até que se exclua completamente a possibilidade de patogenicidade do GBV-C nessa situação.TEDEBV UNIFESP: Teses e dissertaçõesFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)FAPESP: 05/57611-5Universidade Federal de São Paulo (UNIFESP)Granato, Celso Francisco Hernandes [UNIFESP]Universidade Federal de São Paulo (UNIFESP)Baggio-Zappia, Giovana Lotici [UNIFESP]2015-07-22T20:49:34Z2015-07-22T20:49:34Z2009-06-24info:eu-repo/semantics/doctoralThesisinfo:eu-repo/semantics/publishedVersion152 p.application/pdfBAGGIO-ZAPPIA, Giovana Lótici. Avaliação de parâmetros da resposta imunológica na co-infecção pelo HIV-1 e vírus das hepatites C e G (HGV/GBV-C). 2009. 152 f. Tese (Doutorado em Ciências) - Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, 2009.Publico-160.pdfhttp://repositorio.unifesp.br/handle/11600/9067porinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP2024-08-05T10:30:13Zoai:repositorio.unifesp.br/:11600/9067Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestbiblioteca.csp@unifesp.bropendoar:34652024-08-05T10:30:13Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false
dc.title.none.fl_str_mv Avaliação de parâmetros da resposta imunológica na co-infecção pelo HIV-1 e vírus das hepatites C e G (HGV/GBV-C)
Evaluation of parameters of immune response in co-infection with HIV-1 virus and hepatitis C and G (HGV / GBV-C)
title Avaliação de parâmetros da resposta imunológica na co-infecção pelo HIV-1 e vírus das hepatites C e G (HGV/GBV-C)
spellingShingle Avaliação de parâmetros da resposta imunológica na co-infecção pelo HIV-1 e vírus das hepatites C e G (HGV/GBV-C)
Baggio-Zappia, Giovana Lotici [UNIFESP]
HIV-1
Vírus GB C
Hepacivirus
HIV-1
GB virus C
Hepacivirus
title_short Avaliação de parâmetros da resposta imunológica na co-infecção pelo HIV-1 e vírus das hepatites C e G (HGV/GBV-C)
title_full Avaliação de parâmetros da resposta imunológica na co-infecção pelo HIV-1 e vírus das hepatites C e G (HGV/GBV-C)
title_fullStr Avaliação de parâmetros da resposta imunológica na co-infecção pelo HIV-1 e vírus das hepatites C e G (HGV/GBV-C)
title_full_unstemmed Avaliação de parâmetros da resposta imunológica na co-infecção pelo HIV-1 e vírus das hepatites C e G (HGV/GBV-C)
title_sort Avaliação de parâmetros da resposta imunológica na co-infecção pelo HIV-1 e vírus das hepatites C e G (HGV/GBV-C)
author Baggio-Zappia, Giovana Lotici [UNIFESP]
author_facet Baggio-Zappia, Giovana Lotici [UNIFESP]
author_role author
dc.contributor.none.fl_str_mv Granato, Celso Francisco Hernandes [UNIFESP]
Universidade Federal de São Paulo (UNIFESP)
dc.contributor.author.fl_str_mv Baggio-Zappia, Giovana Lotici [UNIFESP]
dc.subject.por.fl_str_mv HIV-1
Vírus GB C
Hepacivirus
HIV-1
GB virus C
Hepacivirus
topic HIV-1
Vírus GB C
Hepacivirus
HIV-1
GB virus C
Hepacivirus
description GBV-C co-infection is frequent in humans and could last for years without clinical symptoms. GBV-C is a flavivirus composed by a single positive RNA strain, closely related to HCV. Initially in its discovery GBV-C was associated with non-A-B hepatitis. However, subsequent studies failed to associate GBV-C with any known human disease and the virus became neglected until a series of studies associated the virus with prolonged survival in HIV infected recipients. Studies evaluating the co-infection presents conflicting results whereas triple HIV-HCV-GBV-C infection remains to be clarified. With the aim to evaluate the effect of GBV-C upon HIV and HIV-HCV co-infected patients, we included a cohort of 159 HIV-seropositive patients from CCDI-UNIFESP. The patients were tested for the presence of anti-E2 antibodies and GBV-C RNA. Of the 107 HIV seropositive patients negative to HCV infection, 41 (38,3%) were positive to GBV-C infection markers, of whom 17 (15,8%) were GBV-C viremic and 24 (22,4%) were positive to anti-E2 antibodies. Of the 52 HIV-HCV co-infected patients, 24 (46,1%) were positive to GBV-C infection markers, of whom 14 (26,9%) were viremic and 10 (19,2%) presented anti-E2 antibodies. Epidemiological data were collected; virological and immunological markers and also hepatic function were evaluated. Besides, IFN- and IL-2 production on CD4, T CD8 and T cells and CD38 activation marker on T CD4 and T CD8 cells were also evaluated. No significant differences on HIV viral load nor on T CD4 and T CD8 cell counts were observed, according to the infection profile. Immune response, evaluated by the IFN- and IL-2 production and by the CD38 expression did not differ among the groups studied. Univariate analysis demonstrated higher ALT, AST and GGT levels in the HIV-HCV co-infetced and HIVHCV- GBV-C triple infected patients. The multivariate analysis demonstrated that the GBV-C influences ALT levels on triple infected patients. Our results demonstrate that GBV-C does not exerts beneficial effects upon chronically HIV infected patients, unlike, it can cause hepatic overload, as demonstrated by the higher ALT levels in the HIV-HCV-GBV-C triple infected patients. In the light of these results, is reasonable to prudently consider this interaction until the possible pathological role of GBV-C on this situation is completely excluded.
publishDate 2009
dc.date.none.fl_str_mv 2009-06-24
2015-07-22T20:49:34Z
2015-07-22T20:49:34Z
dc.type.driver.fl_str_mv info:eu-repo/semantics/doctoralThesis
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format doctoralThesis
status_str publishedVersion
dc.identifier.uri.fl_str_mv BAGGIO-ZAPPIA, Giovana Lótici. Avaliação de parâmetros da resposta imunológica na co-infecção pelo HIV-1 e vírus das hepatites C e G (HGV/GBV-C). 2009. 152 f. Tese (Doutorado em Ciências) - Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, 2009.
Publico-160.pdf
http://repositorio.unifesp.br/handle/11600/9067
identifier_str_mv BAGGIO-ZAPPIA, Giovana Lótici. Avaliação de parâmetros da resposta imunológica na co-infecção pelo HIV-1 e vírus das hepatites C e G (HGV/GBV-C). 2009. 152 f. Tese (Doutorado em Ciências) - Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, 2009.
Publico-160.pdf
url http://repositorio.unifesp.br/handle/11600/9067
dc.language.iso.fl_str_mv por
language por
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 152 p.
application/pdf
dc.publisher.none.fl_str_mv Universidade Federal de São Paulo (UNIFESP)
publisher.none.fl_str_mv Universidade Federal de São Paulo (UNIFESP)
dc.source.none.fl_str_mv reponame:Repositório Institucional da UNIFESP
instname:Universidade Federal de São Paulo (UNIFESP)
instacron:UNIFESP
instname_str Universidade Federal de São Paulo (UNIFESP)
instacron_str UNIFESP
institution UNIFESP
reponame_str Repositório Institucional da UNIFESP
collection Repositório Institucional da UNIFESP
repository.name.fl_str_mv Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)
repository.mail.fl_str_mv biblioteca.csp@unifesp.br
_version_ 1814268292875943936